日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
World
Home / World / World Watch

A vaccine for all nations should be global focus

By Alfred Romann | China Daily Global | Updated: 2020-11-04 09:11
Share
Share - WeChat
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken Oct 30, 2020. [Photo/Agencies]

The push to find a vaccine against COVID-19 is often depicted as a race between companies, or between countries, or even between science and a virus, or between biotechnology and immunity.

This idea of a race with winners and losers may be a handy metaphor, but it may also be counterproductive. In any race, there is one winner and a whole bunch of losers. Follow that train of thought and the result is a winner with a population protected against COVID-19 and a whole bunch of losers that are left to dangle in the wind.

This idea of the race is embodied in the visible trend of vaccine nationalism, which has led countries to commit hundreds of billions of dollars on vaccines that have not even been developed yet. They are spending that money to secure doses of vaccines for their own populations first.

This, according to the World Health Organization, could slow down the effort to come out on the other side of this pandemic as countries fend for themselveswith rich countries likely doing it better than poorer ones. Vaccine nationalism could slow down the global economic recovery and keep travel disruptions in place for much longer.

The only way to really do away with COVID-19 and return to normalcy-dining out, all children back in school, a resurgence in travel and tourism, the occasional party-may be through a coordinated and thought-out approach to vaccine distribution.

Effective multilateral efforts may be the only way for everyone to truly overcome COVID-19, not just those who can afford a vaccine or to dole out trillions of dollars in stimulus measures to shore up their economies.

There is a multinational effort underway to facilitate the global distribution of COVID-19 vaccines once they are available. The COVAX initiative is being led by the WHO and Gavi (the Vaccine Alliance), along with the Coalition for Epidemic Preparedness Innovations. Once vaccines become available, COVAX aims to purchase 2 billion doses for global distribution.

The goal of COVAX is to provide vaccines to 3 percent of the population of each member country that is most at risk and to share the costs of research and distribution between developed and developing countries.

China announced it had signed up to COVAX on Oct 8. It had earlier pledged its support and committed to setting affordable prices for vaccines developed in the country.

COVAX would also allow participating countries to buy enough vaccine to eventually cover as much as half of their populations. Few developed countries are buying that much from it, choosing instead to secure their own supplies, but many are using COVAX as something of an insurance for any overflow.

So far, 184 countries have signed up to COVAX.

The United States is the only major economy to say it will not join the effort. The administration of US President Donald Trump has said it will not be "constrained by multilateral organizations" influenced by the World Health Organization. In the global fight against COVID-19, it sometimes feels like it is the US versus the world.

At least four Chinese biotech companies are carrying out late-stage trials for their COVID-19 vaccines in countries around the world.

Sinovac, which is developing CoronaVac, is testing its vaccine in China and Brazil. The governor of Sao Paulo state told reporters on Oct 19 that CoronaVac is the safest of the various vaccines Brazil is testing.

Sinopharm, which is developing two vaccines, is also testing one in Brazil as well as in Bahrain and the United Arab Emirates. The company has reportedly agreed to carry out trials in Peru, Morocco and Pakistan.

CanSino Biologics is testing its vaccine in China and Saudi Arabia and has a partnership with Russia.

Along the same lines, China's BGI Genomics, the largest genetic testing company of its kind, is opening a plant in Ethiopia to provide COVID-19 tests in Africa.

Other global pharmaceutical companies, including Moderna, AstraZeneca and Johnson & Johnson, are testing vaccines in multiple places.

Even after the vaccines are approved, manufacturing and distribution will be a challenge. Testing a vaccine in multiple countries is one thing, and manufacturing in multiple places is quite another, while transportation and delivery also pose a challenge.

Not all countries have the facilities to manufacture vaccines or the infrastructure in place to distribute them-infrastructure such as effective cold chains to keep the vaccines in good condition and safe, and the ability to ensure that recipients get the expected two shots that most vaccines will likely require.

Vaccine nationalism has already emerged as a concern, even before trials are concluded. Rich nations have committed to buying huge numbers of doses. Poor nations, not so much. In Africa, for example, vaccines are only being tested in South Africa-the country is testing vaccines being developed by US company Novavax and the United Kingdom's Jenner Institute.

The desire to protect a domestic population first is understandable, but losing sight of the fact that the world is now, more than ever, globalized may be counterproductive.

Vaccine nationalism could both shape and slow down the global response to COVID-19.

Getting past the barriers created by the unilateral efforts of countries to secure vaccines for their own people first and prioritizing a coordinated global response will ultimately be the key to getting the entire world back to some kind of normalcy sooner rather than later.

The alternative, the one we are heading toward now, is a splotchy response that results in some countries opening up first and others, more likely the poorer ones, being left behind.

The writer is the managing director of Bahati Ltd, a Hong Kong-based editorial services consultancy. The views do not necessarily reflect those of China Daily.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 在线观看国产一区二区三区 | 五月天综合久久 | 久久九九热 | 永久免费看片视频教学 | 精品国产一区二区三区久久久蜜月 | 欧美日韩在线播放视频 | 成人永久免费视频 | 日本三级精品 | 蜜臀av一区二区三区有限公司 | av在线天堂 | 久久网址 | 九一精品 | 日韩av网站在线 | 国产又大又黄的视频 | 免费看av的网址 | 男女aa视频 | 午夜视频在线观看一区 | 日本一区二区在线视频 | 久久午夜免费视频 | 这里只有精品视频在线观看 | 毛片毛片毛片 | xxxx亚洲| 日韩一区二区三区在线 | 国产福利在线看 | 超碰爱爱 | 国产精品久久久久久久天堂第1集 | 国产经典三级在线 | 天天综合网天天综合 | 成人在线精品视频 | 婷婷色视频 | 伊人久久成人 | 日韩亚洲欧美中文字幕 | 久久精品视频免费看 | 婷婷视频在线观看 | 福利资源在线 | 久久久久99精品国产片 | 亚洲美女在线视频 | 久久精品99国产国产精 | 毛片毛片毛片毛片毛片毛片 | 日韩精品色哟哟 | 91在线小视频 |